The catastrophic failure of Pfizer's torcetrapib looked like it might doom an entire class of cholesterol modulators, but next month Merck will move its anacetrapib into one of the largest cardiovascular trials ever. Asher Mullard investigates how drug developers have reignited hope for the CETP inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Learning lessons from Pfizer's $800 million failure. Nat Rev Drug Discov 10, 163–164 (2011). https://doi.org/10.1038/nrd3401
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3401
This article is cited by
-
Clinical and Regulatory Features of Drugs Not Initially Approved by the FDA
Clinical Pharmacology & Therapeutics (2013)
